Content area
Full text
District-based US Bioservices recently sold $60 million in preferred stock to venture capital firm Whitney & Co. in a private placement that allows the drug distribution company to continue expanding.
Through eight distribution centers across the country, US Bioservices delivers specialized pharmaceuticals from the manufacturer to the patient. The drugs often are innovative therapies that cost in excess of $10,000 per year and have to be injected.
"We focus on smaller populations who suffer from chronic diseases that are on regimented medical treatments," says Ethan...